Weight-Loss drug for lung cancer patients put to the test
NCT ID NCT07477808
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a liquid form of megestrol acetate (a drug that stimulates appetite) can help malnourished people with non-small cell lung cancer gain weight while they receive standard chemotherapy. About 116 participants will be randomly assigned to get either the drug plus standard treatment or standard treatment alone. The main goal is to see if body weight improves over 12 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
megestrol acetate oral suspension
What this could lead to
If it works, this could provide a way to help lung cancer patients maintain or gain weight during chemotherapy, improving their strength and quality of life.
What could go wrong
This is an early-stage trial with only 116 participants, so results may not apply to everyone. The drug may cause side effects like blood clots or fluid retention, and weight gain may not improve cancer outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••